Skip to main content
  • Poster presentation
  • Open access
  • Published:

Cost-efficacy analysis of the MONET trial using Spanish antiretroviral drug prices


In virologically suppressed patients, switching to DRV/r monotherapy maintains HIV RNA suppression, and could also lower treatment costs.


In the MONET trial 256 patients with HIV RNA <50 copies/mL on current HAART for over 24 weeks (NNRTI based (43%), or PI based (57%)), switched to DRV/r 800/100 mg once daily, either as monotherapy (n=127) or with 2NRTI (n=129). The Spanish costs per patient with HIV RNA below 50 copies/mL were calculated, using a "switch included" analysis at Week 96, to account for additional antiretrovirals taken after initial treatment failure. Published prices were used.


In the ITT switch included analysis, HIV RNA <50 copies/mL by Week 96 was 92.1% versus 90.7% in the DRV/r monotherapy and control arms. No patients in either arm developed phenotypic resistance to DRV. Before the trial, the mean annual cost of antiretrovirals was €4612 for patients on NNRTI based HAART, and €9217 for patients on PI based HAART. During the MONET trial, the mean annual per-patient cost of antiretrovirals was €9915 in the triple therapy arm, of which 45% was from NRTIs and 55% from PIs. The mean per-patient cost in the monotherapy arm was €5915, a saving of 40%. We estimated 65,000 people treated with antiretrovirals in Spain (50% NNRTI based, 50% PI based) and 15% of patients (9,750) eligible for PI monotherapy. A switch to DRV/r monotherapy could cut the two-year cost of antiretroviral treatment for these patients, from €137 million to €115 million, a saving of €22 million over two years.


Based on the MONET results, the lower cost of DRV/r monotherapy versus triple therapy in Spain would allow more patients to be treated for a fixed budget, or a saving of up to €22 million over two years, if all eligible patients were switched, while maintaining HIV RNA suppression below 50 copies/mL.

Author information

Authors and Affiliations


Rights and permissions

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Arribas, J., Hill, A., Garcia, I. et al. Cost-efficacy analysis of the MONET trial using Spanish antiretroviral drug prices. JIAS 13 (Suppl 4), P235 (2010).

Download citation

  • Published:

  • DOI: